References
- 1. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade™) in the treatment of multiple myeloma, Ther and Clin Risk Manag. 2006; 2:271-9.
- 2. Romaniuk W, Ołdziej AE, Zińczuk J, Kłoczko J. Proteasome inhibitors in cancer therapy. Postepy Hig Med Dosw. 2015;69: 1443-50.
- 3. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16:3267-85.
- 4. Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016; 105:210-5.
- 5. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-64.
- 6. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. J Biol Chem. 2003;278: 33714-23.
- 7. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24:9695-704.
- 8. Ning YM, He K, Dagher R, Sridhara R, Farrell AT, Justice R et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology. 2007;21:1503-8.
- 9. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:230-69.
- 10. https://clinicaltrials.gov/ct2/results?cond=&term=bortezomib%2C+doxorubicin&cntry=&state=&city=&dist= open access: 01.09.2018
- 11. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal. 2017;7:e577.
- 12. ClinicalTrials.gov Identifier: NCT00440726
- 13. https://clinicaltrials.gov/ct2/show/NCT00440726?term=bortezomib%2C+doxorubicin&cond=ALL%2C+Childhood&rank=1 open access: 01.09.2018
- 14. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther and Clin Risk Manag. 2009;5:151-9.
- 15. Horton TM, Gannavarapu A, Blaney SM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13-23.
- 16. Irimia R, Tofolean IT, Sandu RG, Băran OE, Ceauşescu MC, Coşoreanu V et al. Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia. Documenta Haematologica. 2015;24.